Relay Therapeutics, Inc.
RLAY
Classifica tra le azioni
#4397
Relay Therapeutics, Inc. is a precision medicine company currently engaged in... Relay Therapeutics, Inc. is a precision medicine company currently engaged in clinical trials. Its central mission involves revolutionizing the drug discovery process, with a particular focus on enhancing the creation of small molecule therapies for specific types of cancer and genetic conditions. The company's pipeline features several promising drug candidates: RLY-4008, an orally administered small molecule designed to inhibit fibroblast growth factor receptor 2 (FGFR2), which is undergoing its initial human trials for patients with advanced or metastatic solid tumors exhibiting FGFR2 alterations; RLY-2608, a leading program targeting mutant phosphoinositide 3 kinase alpha (PI3Ka); and RLY-1971, another oral small molecule, an inhibitor of SHP2 (protein tyrosine phosphatase Src homology region 2 domain-containing phosphatase-2), currently in Phase 1 trials for individuals with advanced solid tumors. Relay Therapeutics has established strategic partnerships, including a collaboration with D. E. Shaw Research, LLC, which utilizes computational modeling to analyze protein motion for the identification and development of therapeutic compounds. Furthermore, an agreement with Genentech, Inc. supports the development and commercialization of RLY-1971. Founded in 2015 as Allostery, Inc., the company rebranded to Relay Therapeutics, Inc. in December of that year and maintains its headquarters in Cambridge, Massachusetts.
Prezzo delle azioni
$16.24
Ultima sincronizzazione: 2026-10-16
Capitalizzazione di mercato
$3.56B
Variazione (1 giorno)
-6.13%
Variazione (1 anno)
150.23%
Paese
US
Scambia Relay Therapeutics, Inc. (RLAY)
Categoria
Healthcare
Margine operativo per Relay Therapeutics, Inc. (RLAY)
Margine operativo al October 2026 TTM: -2,999.38%
Secondo gli ultimi rapporti finanziari e il prezzo delle azioni di Relay Therapeutics, Inc., il margine operativo attuale (TTM) è -2,999.38%. Alla fine del 2023, il margine operativo era -1,460.11%.
Storico del margine operativo per Relay Therapeutics, Inc. da 2018 a 2026
Margine operativo alla fine di ogni anno
| Anno | Margine Operativo | Cambia |
|---|---|---|
| 2026 (TTM) | -2,999.38% | -19.42% |
| 2024 | -3,722.07% | 154.92% |
| 2023 | -1,460.11% | -93.26% |
| 2022 | -21,670.89% | 79.99% |
| 2021 | -12,040.21% | 17,734.71% |
| 2020 | -67.51% | 0.00% |
| 2019 | 0.00% | 0.00% |
| 2018 | 0.00% | 0.00% |
Margine operativo per aziende simili o concorrenti
| Azienda | Margine Operativo | Differenza del margine operativo | Il paese |
|---|---|---|---|
| 38.59% | -100.01% |
US
|
|
| -149.01% | -99.95% |
US
|
|
| 25.57% | -100.01% |
AU
|
|
| 0.00% | - |
CH
|
|
| 28.81% | -100.01% |
NL
|
Cos'è l'Margine operativo di un'azienda?
L'Margine operativo è un indicatore chiave per valutare la redditività di un'azienda. Margini operativi più elevati sono generalmente preferibili poiché indicano che l'azienda riesce a vendere i propri prodotti o servizi a un prezzo significativamente superiore rispetto ai costi di produzione. Si calcola dividendo gli utili per i ricavi.